🇺🇸 Olodaterol-Tiotropium in United States

429 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 429

Most-reported reactions

1. Dyspnoea — 70 reports (16.32%)
2. Wheezing — 67 reports (15.62%)
3. Asthma — 65 reports (15.15%)
4. Cough — 47 reports (10.96%)
5. Loss Of Personal Independence In Daily Activities — 36 reports (8.39%)
6. Therapeutic Product Effect Incomplete — 36 reports (8.39%)
7. Chest Discomfort — 27 reports (6.29%)
8. Drug Ineffective — 27 reports (6.29%)
9. Pneumonia — 27 reports (6.29%)
10. Sleep Disorder Due To A General Medical Condition — 27 reports (6.29%)

Source database →

Frequently asked questions

Is Olodaterol-Tiotropium approved in United States?

Olodaterol-Tiotropium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Olodaterol-Tiotropium in United States?

Fraunhofer-Institute of Toxicology and Experimental Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.